Newsfeed

Every published oncology item from an approved source, most recent first. No account required — this is the unfiltered stream, not personalized to any follows.

Items are tagged with the biomarkers and tumour types they resolve to; each tag opens that record, and every record’s page carries the same items back.

This demo serves a captured snapshot of the feed, not a live connection to the sources.

PubMed Central · Feb 27, 2026
Chemotherapeutic Potential of Fluorouracil-Platinum (IV) Prodrugs Against Cisplatin-Resistant Colorectal Cancer Cells.
- colorectal cancer (tumour type)
Read at PubMed Central
PubMed Central · Feb 24, 2026
Early response of total neoadjuvant therapy with regional deep hyperthermia for low-lying locally advanced rectal cancer: a single-center retrospective study.
- colorectal cancer (tumour type)
Read at PubMed Central
PubMed Central · Feb 20, 2026
The AI Act and the MDR post-market requirements for semiautonomous AI SaMD: a radiology case study in prostate cancer.
- prostate cancer (tumour type)
Read at PubMed Central
PubMed Central · Feb 18, 2026
RAB1A is a novel vulnerability in uveal melanoma revealed by dual inhibition of MNK1/2 and mTOR.
- melanoma (tumour type)
Read at PubMed Central
PubMed Central · Feb 6, 2026
Extracellular vesicle biomarkers in pancreatic ductal adenocarcinoma: from bulk detection to single-extracellular vesicle profiling and endoscopic liquid biopsy.
- pancreatic cancer (tumour type)
Read at PubMed Central
PubMed Central · Feb 4, 2026
SPME-based investigation of thapsigargin-induced alterations in the volatilome of human melanoma cells.
- melanoma (tumour type)
Read at PubMed Central
National Cancer Institute · Jan 30, 2026
Researchers identify new blood markers that may detect early pancreatic cancer
National Institutes of Health (NIH)-supported investigators have developed a blood test to find pancreatic ductal adenocarcinoma, one of the deadliest forms of cancer. The new test could improve survival rates from pancreatic cancer, which tends to be diagnosed at late stages when therapy is less likely to be effective. The findings were published in Clinical Cancer Research.
- pancreatic cancer (tumour type)
View original at National Cancer Institute
PubMed Central · Jan 29, 2026
Loss of BOK increases vulnerability of p53 deficient non-small cell lung cancer cells to ATR inhibition through its role in uridine metabolism.
- non-small cell lung cancer (tumour type)
Read at PubMed Central
PubMed Central · Jan 8, 2026
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study.
- prostate cancer (tumour type)
Read at PubMed Central
PubMed Central · Jan 7, 2026
Validation of the Prostatype® P-score for predicting prostate cancer specific mortality in a multiethnic U.S. veterans cohort.
- prostate cancer (tumour type)
Read at PubMed Central
PubMed Central · Jan 6, 2026
Tributyltin Protumorigenic Effects Targeting Prostate Cancer Cell Metabolism, Proliferation, Migration, and Invasion.
- prostate cancer (tumour type)
Read at PubMed Central
PubMed Central · Dec 26, 2025
Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment.
- prostate cancer (tumour type)
Read at PubMed Central
PubMed Central · Dec 19, 2025
Gymconopin C exhibits anti-non-small cell lung cancer effect by regulating miR-6777-5p/ADRB2 pathway to promote mitophagy.
- non-small cell lung cancer (tumour type)
Read at PubMed Central
PubMed Central · Dec 11, 2025
Progression of index metastases in oligometastatic hormone-sensitive prostate cancer: implications for metastases directed therapy?
- prostate cancer (tumour type)
Read at PubMed Central
National Cancer Institute · Dec 10, 2025
NIH-led study reveals role of mobile DNA elements in lung cancer progression
Using lung cancer biospecimens from the Sherlock-Lung study, an international team led by National Institutes of Health (NIH) researchers, identified key factors that drive tumor evolution and influence outcomes. Overall, the findings, published Dec. 10, 2025, in Nature, describe a previously unknown origin of some aggressive lung cancers.
View original at National Cancer Institute
PubMed Central · Dec 9, 2025
Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data.
- prostate cancer (tumour type)
Read at PubMed Central
PubMed Central · Dec 9, 2025
Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer.
- prostate cancer (tumour type)
Read at PubMed Central
PubMed Central · Dec 1, 2025
Intratumoral microbiota in colorectal cancer: roles, therapeutic potential, and challenges.
- colorectal cancer (tumour type)
Read at PubMed Central
PubMed Central · Nov 24, 2025
Sex disparities in melanoma stage, recurrence and mortality: A Danish cohort study, 2004 to 2024.
- melanoma (tumour type)
Read at PubMed Central
PubMed Central · Nov 1, 2025
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis.
- prostate cancer (tumour type)
Read at PubMed Central

Newsfeed

Chemotherapeutic Potential of Fluorouracil-Platinum (IV) Prodrugs Against Cisplatin-Resistant Colorectal Cancer Cells.

Early response of total neoadjuvant therapy with regional deep hyperthermia for low-lying locally advanced rectal cancer: a single-center retrospective study.

The AI Act and the MDR post-market requirements for semiautonomous AI SaMD: a radiology case study in prostate cancer.

RAB1A is a novel vulnerability in uveal melanoma revealed by dual inhibition of MNK1/2 and mTOR.

Extracellular vesicle biomarkers in pancreatic ductal adenocarcinoma: from bulk detection to single-extracellular vesicle profiling and endoscopic liquid biopsy.

SPME-based investigation of thapsigargin-induced alterations in the volatilome of human melanoma cells.

Researchers identify new blood markers that may detect early pancreatic cancer

Loss of BOK increases vulnerability of p53 deficient non-small cell lung cancer cells to ATR inhibition through its role in uridine metabolism.

Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study.

Validation of the Prostatype® P-score for predicting prostate cancer specific mortality in a multiethnic U.S. veterans cohort.

Tributyltin Protumorigenic Effects Targeting Prostate Cancer Cell Metabolism, Proliferation, Migration, and Invasion.

Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment.

Gymconopin C exhibits anti-non-small cell lung cancer effect by regulating miR-6777-5p/ADRB2 pathway to promote mitophagy.

Progression of index metastases in oligometastatic hormone-sensitive prostate cancer: implications for metastases directed therapy?

NIH-led study reveals role of mobile DNA elements in lung cancer progression

Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data.

Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer.

Intratumoral microbiota in colorectal cancer: roles, therapeutic potential, and challenges.

Sex disparities in melanoma stage, recurrence and mortality: A Danish cohort study, 2004 to 2024.

DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis.